These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 22095012)

  • 1. Pharmaceutical principles of acid inhibitors: unmet needs.
    Krznaric Z; Ljubas Kelecic D; Rustemovic N; Vranesic Bender D; Ostojic R; Markos P; Scarpignato C
    Dig Dis; 2011; 29(5):469-75. PubMed ID: 22095012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy.
    Metz DC; Vakily M; Dixit T; Mulford D
    Aliment Pharmacol Ther; 2009 May; 29(9):928-37. PubMed ID: 19298580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolving issues in the management of reflux disease?
    Yuan Y; Hunt RH
    Curr Opin Gastroenterol; 2009 Jul; 25(4):342-51. PubMed ID: 19417644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving drugs in gastroesophageal reflux disease: pharmacologic treatment beyond proton pump inhibitors.
    Johnson DA; Levy BH
    Expert Opin Pharmacother; 2010 Jun; 11(9):1541-8. PubMed ID: 20450445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weakly acidic reflux.
    Tack J; Blondeau K
    Dig Dis; 2009; 27(1):58-61. PubMed ID: 19439962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of gastroesophageal reflux disease that does not respond well to proton pump inhibitors.
    Hershcovici T; Fass R
    Curr Opin Gastroenterol; 2010 Jul; 26(4):367-78. PubMed ID: 20571388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nocturnal gastroesophageal reflux disease: issues, implications, and management strategies.
    Johnson DA; Katz PO
    Rev Gastroenterol Disord; 2008; 8(2):98-108. PubMed ID: 18641592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological management of GERD: where does it stand now?
    Hershcovici T; Fass R
    Trends Pharmacol Sci; 2011 Apr; 32(4):258-64. PubMed ID: 21429600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are there unmet needs in acid suppression?
    Tytgat GN
    Best Pract Res Clin Gastroenterol; 2004; 18 Suppl():67-72. PubMed ID: 15588797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton pump inhibitors: the beginning of the end or the end of the beginning?
    Scarpignato C; Hunt RH
    Curr Opin Pharmacol; 2008 Dec; 8(6):677-84. PubMed ID: 18840545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proton pump inhibitor failure--what are the therapeutic options?
    Fass R
    Am J Gastroenterol; 2009 Mar; 104 Suppl 2():S33-8. PubMed ID: 19262545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acid-NSAID/aspirin interaction in peptic ulcer disease.
    Hunt RH; Yuan Y
    Dig Dis; 2011; 29(5):465-8. PubMed ID: 22095011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent developments in the pathophysiology and therapy of gastroesophageal reflux disease and nonerosive reflux disease.
    Tack J
    Curr Opin Gastroenterol; 2005 Jul; 21(4):454-60. PubMed ID: 15930988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapy resistance of gastro-oesophageal reflux symptoms: acid reflux, non-acid reflux or no reflux].
    Bredenoord AJ; Smout AJ
    Ned Tijdschr Geneeskd; 2008 Nov; 152(47):2548-52. PubMed ID: 19174935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [PPI treatment for gastric ulcer patients in the elderly].
    Itoh T; Minami M; Naito C; Chiba T
    Nihon Rinsho; 2010 Nov; 68(11):2057-63. PubMed ID: 21061533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Esophageal acid exposure on proton pump inhibitors in unselected asymptomatic gastroesophageal reflux disease patients.
    Grigolon A; Cantù P; Savojardo D; Conte D; Penagini R
    J Clin Gastroenterol; 2008 Oct; 42(9):969-73. PubMed ID: 18719508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
    Huang JQ; Hunt RH
    Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gradual cessation of proton pump inhibitor (PPI) treatment may prevent rebound acid secretion, measured by the alkaline tide method, in dyspepsia and reflux patients.
    Niv Y
    Med Hypotheses; 2011 Sep; 77(3):451-2. PubMed ID: 21723045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evidence and uncertainties on the clinical use of proton pump inhibitors].
    de Prados CM
    Gastroenterol Hepatol; 2010 May; 33 Suppl 1():5-10. PubMed ID: 20728783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Refractory gastrooesophageal reflux disease.
    Bredenoord AJ; Smout AJ
    Eur J Gastroenterol Hepatol; 2008 Mar; 20(3):217-23. PubMed ID: 18301303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.